IVF · INVO Fertility, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”View the 10-Q filed Jun 22, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-12-04 | Szot Matthew K |
Director |
Other↓
Filing footnotes — Common stock (Direct)
The Reporting Person surrendered the shares of Common Stock to the Issuer without receiving any payment or other value in return. |
Common stock
|
3 |
| 2025-12-03 | Szot Matthew K |
Director |
Sell↓
|
Common stock
|
4 |
| 2025-08-26 | Szot Matthew K |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
45,000 |
| 2025-08-26 | DAVIS TRENT D |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
45,000 |
| 2025-08-26 | Ryan Barbara |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
45,000 |
| 2025-08-26 | Messina Rebecca |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
45,000 |
| 2025-08-26 | Goren Andrea |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
50,000 |
| 2025-08-26 | Shum Steve |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Stock Option (right to buy)
|
42,000 |
| 2023-05-18 | Ryan Barbara |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
85,000 |
| 2023-05-18 | Szot Matthew K |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
85,000 |
| 2023-05-18 | Shum Steve |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in twelve equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
100,000 |
| 2023-05-18 | DAVIS TRENT D |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
85,000 |
| 2023-05-18 | Messina Rebecca |
Director |
Award↓
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
85,000 |
| 2023-05-18 | Campbell Michael Jos. |
Director, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in twelve equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock Option (right to buy)
|
83,000 |
| 2023-05-18 | Goren Andrea |
Chief Financial Officer |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option vests in twelve equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. |
Stock option (right to buy)
|
81,000 |
| 2022-06-01 | Szot Matthew K |
Director |
Buy↑
|
Common Stock
|
14,474 |
| 2022-06-01 | Messina Rebecca |
Director |
Buy↑
|
Common Stock
|
9,868 |
| 2022-06-01 | Shum Steve |
Director |
Buy↑
|
Common Stock
|
58,885 |
| 2022-06-01 | Ryan Barbara |
Director |
Buy↑
|
Common Stock
|
10,526 |
| 2022-06-01 | Segal Jeffrey |
Director |
Buy↑
|
Common Stock
|
9,211 |
| 2022-06-01 | Doody Kevin |
Director, Medical Director |
Buy↓
|
Common Stock
|
177,306 |
| 2022-06-01 | Goren Andrea |
Chief Financial Officer |
Buy↑
|
Common Stock
(I)
|
52,632 |
| 2022-06-01 | Campbell Michael Jos. |
Director, Chief Operating Officer |
Buy↑
|
Common Stock
|
10,526 |
| 2022-06-01 | DAVIS TRENT D |
Director |
Buy↑
|
Common Stock
|
11,184 |
| 2022-01-15 | DAVIS TRENT D |
Director |
Award↑
|
Common Stock
|
8,865 |
| 2022-01-15 | Messina Rebecca |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
10,098 |
| 2022-01-15 | Ryan Barbara |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
10,435 |
| 2022-01-15 | Shum Steve |
Director |
Award↑
|
Common Stock
|
20,111 |
| 2022-01-15 | Campbell Michael Jos. |
Director, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of three years from the date of grant. |
Stock Option
|
18,513 |
| 2022-01-15 | Doody Kevin |
Director, Medical Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
9,088 |
| 2022-01-15 | Segal Jeffrey |
Director |
Award↑
|
Common Stock
|
8,034 |
| 2022-01-15 | Goren Andrea |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of three years from the date of grant. |
Stock Option
|
15,197 |
| 2022-01-15 | Segal Jeffrey |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
9,762 |
| 2022-01-15 | DAVIS TRENT D |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vest in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
10,771 |
| 2022-01-15 | Shum Steve |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of three years from the date of grant. |
Stock Option
|
57,018 |
| 2022-01-15 | Campbell Michael Jos. |
Director, Chief Operating Officer |
Award↑
|
Common Stock
|
15,236 |
| 2022-01-15 | Messina Rebecca |
Director |
Award↑
|
Common Stock
|
8,311 |
| 2022-01-15 | Goren Andrea |
Chief Financial Officer |
Award↑
|
Common Stock
|
5,361 |
| 2022-01-15 | Ryan Barbara |
Director |
Award↑
|
Common Stock
|
8,588 |
| 2022-01-15 | Doody Kevin |
Director, Medical Director |
Award↑
|
Common Stock
|
7,480 |
| 2022-01-15 | Szot Matthew K |
Director |
Award↑
|
Common Stock
|
10,250 |
| 2022-01-15 | Szot Matthew K |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests in monthly increments over a period of twelve months from the date of grant. |
Stock Option
|
12,454 |
| 2021-10-05 | Goren Andrea |
Chief Financial Officer |
Buy↑
|
Common Stock
(I)
|
30,674 |
| 2021-10-05 | Shum Steve |
Director |
Buy↑
|
Common Stock
|
30,674 |
| 2021-05-11 | Messina Rebecca |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option vests in substantially equal monthly increments over a period of seven months from the grant date. |
Stock Option
|
6,239 |
| 2021-05-11 | Messina Rebecca |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units, which vest in substantially equal monthly increments over a period of seven months from the grant date. |
Common Stock
|
4,806 |
| 2021-05-10 | AWM Investment Company, Inc. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (QP), Special Situations Cayman Fund, L.P. (Cay) and Special Situations Life Sciences Fund, L.P. (LS). (LS and together with QP and Cay, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 400,559 shares of Common Stock of the Issuer (the Shares) held by QP, 133,516 Shares held by Cay and 625,000 Shares held by LS. Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM. The reporting person disclaims beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. This is a weighted average price |
Common Stock
(I)
|
1,000 |
| 2021-05-06 | AWM Investment Company, Inc. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (QP), Special Situations Cayman Fund, L.P. (Cay) and Special Situations Life Sciences Fund, L.P. (LS). (LS and together with QP and Cay, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 399,809 shares of Common Stock of the Issuer (the Shares) held by QP, 133,266 Shares held by Cay and 625,000 Shares held by LS. Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM. The reporting person disclaims beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. This is a weighted average price. |
Common Stock
(I)
|
1,000 |
| 2021-05-04 | AWM Investment Company, Inc. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
This is a weighted average price. |
Common Stock
(I)
|
2,457 |
| 2021-05-04 | AWM Investment Company, Inc. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
This is a weighted average price. |
Common Stock
(I)
|
465 |